Cord blood

Global Cord Blood & Tissue Banking Industry Market Size, Segmentation & Forecast Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 15, 2024
Health, Biotechnology, Catalent, Transplant, Cell, Patient, UCB, LifeCell International, Microsoft Exchange Server, Organization, Regenerative medicine, Cryo-Cell International, Spectrum, Disorder, Umbilical cord, Population growth, Stemcell Technologies, Certification, HSCT, NIH, GMP, Cord blood, The Cooper Companies, Safety, Hematopoietic stem cell transplantation, Artivion, DSM-IV codes, Tissue, Research, Acquisition, Cancer, Leukemia, CBR, Cryopreservation, Cerebral palsy, FDA, CBUS, Sickle cell disease, ClinicalTrials.gov, Registry, Amniotic fluid, Hearing loss, GCBC, MNC, Geography

The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.
  • There are now over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.
  • Today, nearly all U.S. cord blood banks and approximately one-third of global cord blood banks offer cord tissue storage.
  • The report presents findings on the following topics:
    Rate per cord blood unit in the U.S. and Europe
    Number of clinical trials, number of published scientific papers, and amount of NIH funding for cord blood research
    Number and types of patents for cord blood, cord tissue, and placental products
    The report presents a comprehensive analysis of the global cord blood and tissue banking market.

Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing

Retrieved on: 
Friday, February 9, 2024
DSM-IV codes, CBR, The Cooper Companies, Immunodeficiency, Health, Hearing loss, Genetic testing, EL, Cancer, Diet, Fertility, Epilepsy, Portrait, Genetics, Gene, Cord blood, Vaccine

‍TRUMBULL, Conn. and EL MONTE, Calif., Feb. 9, 2024 /PRNewswire/ -- CooperSurgical®, a global leader in fertility and women's health, and Fulgent Genetics, Inc. (NASDAQ: FLGT), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that they have partnered to offer families of Cord Blood Registry® (CBR®) exclusive newborn genetic screening panels.

Key Points: 
  • CBR Portrait includes more than twice as many genes as CBR Snapshot and may identify more rare causes of these conditions.
  • CBR Landscape also includes a pharmacogenetic (PGx) component, which is a type of genetic testing that can determine how a person breaks down or metabolizes certain medications.
  • "Part of our mission is to use our resources and testing to improve the lives of those around us.
  • Newborn genetic analysis serves as an illustration of this commitment, as early intervention may significantly improve health outcomes for many of these conditions."

Global Cord Blood & Tissue Banking Industry Report 2024 - The Vast Majority of the Global Cord Blood Market is Now Controlled by the World's 10 Largest Cord Blood Banking Operators - ResearchAndMarkets.com

Retrieved on: 
Monday, January 22, 2024
Health, Other Health, GCBC, Catalent, Stemcell Technologies, HSCT, Population growth, Cryopreservation, CBUS, Leukemia, Regenerative medicine, Cord blood, The Cooper Companies, Cerebral palsy, Spectrum, Research, Geography, UCB, LifeCell International, Registry, Hearing loss, Tissue, Cryo-Cell International, Cancer, GMP, ClinicalTrials.gov, Disorder, Acquisition, Sickle cell disease, Safety, Patient, MNC, NIH, Transplant, Certification, FDA, Amniotic fluid, Microsoft Exchange Server, Hematopoietic stem cell transplantation, Cell

There are over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.

Key Points: 
  • There are over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.
  • Today, nearly all U.S. cord blood banks and approximately one-third of global cord blood banks offer cord tissue storage.
  • The vast majority of the global cord blood market is now controlled by the world's 10 largest cord blood banking operators.
  • It reveals the identities of companies offering cord blood storage, cord blood processing technologies, cord blood expansion technologies, and cord blood therapeutics on a global basis.

Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Cord blood, Patient, Lymphoma, HL, PTCL, EST, Cell, GVHD, Affimer, Society, ASH, CFGB-FM, PST, NK, Relapse, Cytokine release syndrome, Abstract, Annual general meeting, Natural killer T cell, ORR, EFS, Haematopoietic system, University, Exposition, Safety, CRS, Cancer, Peripheral T-cell lymphoma, MD Anderson Cancer Center, Investigational New Drug, Pharmaceutical industry, Vaccine, Leukemia

A total of 42 patients were enrolled in the study with 36 patients treated at the RP2D.

Key Points: 
  • A total of 42 patients were enrolled in the study with 36 patients treated at the RP2D.
  • All patients were heavily pretreated and refractory to their most recent line of therapy with active progressive disease at the time of enrollment.
  • A more in-depth analysis of the data and updated EFS/OS data using a later cut-off date will be presented during Dr. Nieto’s oral presentation.
  • The second presentation will be a poster featuring the design of Affimed’s phase 2 LuminICE-203 clinical trial investigating AFM13 in combination with Artiva’s AlloNK® (also known as AB-101), an allogeneic, non-genetically modified NK cell therapy candidate.

Cord Blood Registry® Announces Thought Leadership Role at Cord Blood Connect

Retrieved on: 
Friday, September 8, 2023
Tissue, Education, Research, Medicine, Cord blood, CBR, Science, Patient, The Cooper Companies, Fertility, Health, Family, Pharmaceutical industry

TRUMBULL, Conn., Sept. 8, 2023 /PRNewswire/ -- CooperSurgical, a global leader in fertility and women's health, announced that Cord Blood Registry® (CBR®) will have a key role in the upcoming Cord Blood Connect meeting from September 8th – 11th, which is the annual meeting of the Cord Blood Association. The Cord Blood Association is an international nonprofit organization that promotes both public and family newborn stem cell preservation and accelerates the use of cord blood and birthing tissues to benefit patients and advance medicine.

Key Points: 
  • TRUMBULL, Conn., Sept. 8, 2023 /PRNewswire/ -- CooperSurgical, a global leader in fertility and women's health, announced that Cord Blood Registry® (CBR®) will have a key role in the upcoming Cord Blood Connect meeting from September 8th – 11th, which is the annual meeting of the Cord Blood Association.
  • "Cord Blood Connect is a critical meeting for public and family cord blood banks, allowing them a forum to discuss industry innovations, patient needs, and evolving industry standards," stated Holly Sheffield, President, CooperSurgical.
  • CBR's abstract titled "Experience with enrollments and releases within a medical needs program at a large U.S. private cord blood bank" was accepted as a poster presentation at Cord Blood Connect.
  • Mr. Bawin will be moderating a panel titled "Future of Cord Blood Banking" on Saturday, September 9th featuring global leaders from the major family and public cord blood banks.

Be The Match BioTherapies® Marks Cord Blood Awareness Month with the Announcement of the Cord Blood Bank Alliance

Retrieved on: 
Monday, July 10, 2023
Health, National Marrow Donor Program, Stem Cell Therapeutic and Research Act of 2005, Cord, The Cord of Life, Research, Cord blood, Government, MD, Patient, Bloodworks Northwest, NMDP, Blood, Cord blood bank, Stem cell, CBUS, Environment, Pharmaceutical industry, Medical device, Match

MINNEAPOLIS, July 10, 2023 (GLOBE NEWSWIRE) -- In anticipation of Cord Blood Awareness Month this July, Be The Match BioTherapies ® , an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced the formation of the Be The Match BioTherapies Cord Blood Bank Alliance (CBBA).

Key Points: 
  • MINNEAPOLIS, July 10, 2023 (GLOBE NEWSWIRE) -- In anticipation of Cord Blood Awareness Month this July, Be The Match BioTherapies ® , an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced the formation of the Be The Match BioTherapies Cord Blood Bank Alliance (CBBA).
  • Members include Bloodworks Northwest, the Cleveland Cord Blood Center, Cord for Life, the Carolinas Cord Blood Bank, Vitalant, South Texas Blood & Tissue, Versiti, and StemCyte.
  • In this role, the organization works with public cord blood banks, doctors and researchers to continually improve cord blood transplantation and educate medical professionals and the public.
  • This work expanded the organization’s deep relationships with cord blood banks and positioned it to take a leadership role in creating the CBBA.

The first Post-COVID Syndrome Phase II clinical trial has begun recruiting patients.

Retrieved on: 
Thursday, May 25, 2023
Smell, Medicine, Taiwan, US Food Sovereignty Alliance, 2000 Goody's Body Pain 500, Long COVID, Fatigue, Arthralgia, Chills, COVID-19, Clinical trial, Food and Drug Administration, Chest pain, Statistics, Research, Brain, Multimedia, Cough, Cord blood, Myalgia, Patient, HPC, Timeline of the COVID-19 pandemic in the United Kingdom, WHO, FDA, Headache, Food, Pfizer, Pharmaceutical industry

BALDWIN PARK, Calif., May 25, 2023 /PRNewswire/ -- StemCyte announced it has officially begun recruiting patients under a US Food and Drug Administration (FDA) approved Phase IIa human clinical trial in the United States.

Key Points: 
  • BALDWIN PARK, Calif., May 25, 2023 /PRNewswire/ -- StemCyte announced it has officially begun recruiting patients under a US Food and Drug Administration (FDA) approved Phase IIa human clinical trial in the United States.
  • This is the world's first Phase II trial using umbilical cord blood cells to treat Post-COVID syndrome.
  • Cord Blood is a cell therapy biological drug that StemCyte is investigating to repair symptoms of Post-COVID Syndrome.
  • Currently, Pfizer's Paxlovid Phase III clinical trial and StemCyte's HPC, Cord Blood complement each other in treating Post-COVID Syndrome.

$2.83 Billion Worldwide Cord Blood Banking Services Industry to 2027 - Featuring Alphacord, Americord Registry, ATCC and California Cryobank Among Others

Retrieved on: 
Monday, October 24, 2022
Leukemia, Placenta, Cord blood, Therapy, Prevalence, B cell, Lymphoma, Red blood cell, Smoking, LifeBank, CAGR, Patient, Hospital, Research, Collection, Cancer, Lists of diseases, Bone marrow, R, Industry, Stem cell, Awareness, PerkinElmer, White blood cell, Umbilical cord, COVID-19, ATCC, Hematology, Pharmaceutical industry, Cryptocurrency, Potash, California Cryobank, Growth

The global cord blood banking services market reached a value of US$ 1.48 Billion in 2021.

Key Points: 
  • The global cord blood banking services market reached a value of US$ 1.48 Billion in 2021.
  • Cord blood banking is a procedure of collecting and storing life-saving stem cells from the umbilical cord and placenta for future use.
  • Moreover, there is an increase in the utilization of cord blood banking services for the treatment of immunodeficiency disorders across the globe.
  • What is the structure of the global cord blood banking services market and who are the key players?

Global Cord Blood Banking Services Market (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 13, 2022
Infectious Diseases, Health, Oncology, Stem Cells, Leukemia, Placenta, Cord blood, Prevalence, Growth, B cell, Lymphoma, Red blood cell, Smoking, Patient, Hospital, Research, Collection, Bone marrow, Cancer, Lists of diseases, R, Industry, Awareness, Stem cell, White blood cell, Umbilical cord, COVID-19, Hematology, Pharmaceutical industry, Cryptocurrency, Potash

Cord blood banking is a procedure of collecting and storing life-saving stem cells from the umbilical cord and placenta for future use.

Key Points: 
  • Cord blood banking is a procedure of collecting and storing life-saving stem cells from the umbilical cord and placenta for future use.
  • Key Questions Answered in This Report:
    How has the global cord blood banking services market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global cord blood banking services market?
  • What is the structure of the global cord blood banking services market and who are the key players?

Discover Medical Advances in Cellular Therapy Research Using Cord Blood for Cancer, HIV, Cerebral Palsy and Autism During World Cord Blood Day 2022

Retrieved on: 
Thursday, October 13, 2022
Method, CBA, Leukemia, Transplant, FACT, Cord blood, Stroke, Laboratory, Partner, Accreditation, Parent, Foundation, Hospital, Research, Hosting, STEM, History, Bone marrow, UCLA, Cancer, HIV, Student, AABB, Temperature, Association, Cerebral palsy, Autism, WCBD, Indiana University, The Sisterhood of the Traveling Pants, Kuehne + Nagel, University Hospitals Cleveland Medical Center, Life, Regenerative medicine, The Sisterhood of the Traveling Pants (novel), NMDP, World Marrow Donor Association, Sisterhood, HIE, Duke University, Pharmaceutical industry, Medical device, Dentistry, Blood

TUCSON, Ariz., Oct. 13, 2022 /PRNewswire/ -- Innovations using cord blood in cellular therapy, including traditional stem cell transplants and regenerative medicine research, will be featured during World Cord Blood Day (WCBD) 2022. Recommended for healthcare professionals, expectant parents and STEM students, the official virtual conference, hosted by Save the Cord Foundation, will be held on November 15th (register free via Eventbrite).

Key Points: 
  • Free virtual conference for World Cord Blood Day 2022 (November 15th) to feature renowned transplant doctors and researchers presenting ground-breaking work in cellular therapy using cord blood to treat cancer, HIV, cerebral palsy and autism.
  • TUCSON, Ariz., Oct. 13, 2022 /PRNewswire/ -- Innovations using cord blood in cellular therapy, including traditional stem cell transplants and regenerative medicine research, will be featured during World Cord Blood Day (WCBD) 2022.
  • Dr. Joanne Kurtzberg (Duke University / Marcus Center for Cellular Cures) to give an in-depth update on advances in clinical trials using cord blood and cord tissue in regenerative medicine for cerebral palsy, autism, HIE and stroke.
  • The Foundation provides non-commercial information to parents, health professionals and the public regarding methods for saving cord blood, as well as current applications using cord blood and the latest research.